Theranostics

From Wikipedia, the free encyclopedia

Theranostics is the term used to describe the proposed process of diagnostic therapy for individual patients - to test them for possible reaction to taking a new medication and to tailor a treatment for them based on the test results.[1]

It encompasses the possible utilisation of a wide range of subjects that includes: predictive medicine, personalized medicine, integrated medicine, pharmacodiagnostics and Dx/Rx partnering

This method is looked upon as the possible end result of new advances made in Pharmacogenomics, Drug Discovery using Genetics, Molecular Biology and Microarray chips technology. [2]

[edit] Etymology

The term was used first by the CEO of PharmaNetics, John Funkhouser. He defined it as, "The ability to affect therapy or treatment of a diseased state."^{[citation needed]}

[edit] References

Picard FJ, Bergeron MG., Rapid molecular theranostics in infectious diseases, Drug Discov Today. 2002 Nov 1;7(21):1092-101.
Hooper JW., The genetic map to theranostics, MLO Med Lab Obs. 2006 Jun;38(6):22-3, 25.